Leading Europe Biotech Digital Media outlet Labiotech ranks Kymab among its nine top companies to watch in 2018
Labiotech has recognised Kymab as one of nine top European companies to watch in 2018, stating that "we are about to see the power of Kymab brought to bear".
Based in Cambridge, UK, Kymab is making better medicines by continually improving the best antibody technologies.
Kymab’s unique technologies drive rapid development of effective, human antibodies across four main therapeutic areas - immuno-oncology, inflammation, haematology and infectious disease.
In the past four months, Kymab has presented promising results on anti-tumour activity of its antibodies KY1003 and KY1044 : it also published in Science Translational Medicine results with KY1005 in graft-versus-host disease (GCHD).
These are among 19 products in Kymab’s published pipeline.
Dr Dave Chiswell, Kymab CEO, said in a September 2017 interview with Labiotech "I think we are getting as close as we can to the best way of making antibodies… We now have three candidates that could be in the clinic in the next two years."
Dr Chiswell was a founder of Cambridge Antibody Technology, which Labiotech ranked in 2017 as one of the seven best biotech companies in Europe’s history.
Notes to Editors
Labiotech.eu is the leading digital media covering the European Biotech industry, read by 70,000+ monthly visitors.
"Happy 2018, Here Are the Top 9 European Biotech Companies To Watch": https://labiotech.eu/biotech-companies-to-watch-2018/
Kymab is a biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary antibody platform which contains a full diversity of human antibodies, making it the most comprehensive antibody development platform available.
Kymab's platform has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding drug candidates with best-in-class characteristics quickly and efficiently.
Kymab is using the platform for its internal drug discovery programmes and in partnership with pharmaceutical companies. Kymab was founded in 2010 and has raised over US$220m of equity financing. It has an experienced management team with a successful track record in drug discovery and development and a broad pipeline of therapeutic antibody programmes in immuno-oncology, auto-immunity, haematology, infectious disease and other areas.
For more information please see http://www.kymab.com